Researchers say they've successfully
eliminated HIV from the DNA of infected mice for the first
time, bringing them one step closer to curing the virus in humans. Scientists
from Temple University and the University of Nebraska Medical Center
were able to eliminate the virus using a combination of gene-editing
technology and a slow-release antiviral drug, according to a study
published Tuesday in Nature Communications.
"The
possibility exists that HIV can be cured," Howard Gendelman, chairman
of UNMC's pharmacology and experimental neuroscience department and
study author. "It’s going to take a little bit of time but to have the
proof of concept gets us all excited."
Nearly 37
million people are living with HIV, according to UNAIDS, which if left
untreated can develop into AIDS. Current HIV treatment involves daily,
lifelong antiretroviral therapy (ART) which suppresses the virus'
ability to replicate, but doesn't eliminate the virus from the body.
If a patient stops taking the drugs, HIV is able to
rebound because the virus is able to "integrate its DNA sequence into
the genomes of cells of the immune system, where it lies dormant and
beyond the reach of antiretroviral drugs," according to a press release.
Researchers
used a new form of ART called LASER ART on 23 "humanized mice," animals
genetically modified to bear similarities to the human immune response.
They were able to control the release and metabolism of the drug which
allowed it to suppress virus replication for longer period of time.
The team then excised the remaining integrated HIV genome using a
gene-editing tool called CRISPR-Cas9 which allows scientists to operate
on DNA to add or disable certain genes
"That’s why we believe this technology is working
because the LASER ART is reducing the virus significantly and then the
CRISPR comes in and it's able to be more effective," Gendelman
said. "They work at different stages, but put together they’re kind of
buddies."
Gendelman emphasized that the
process "only is successful if we get rid of every virus in the body."
The treatment worked on 9 of the 23 mice involved.
"We had to be highly efficient and getting a third of these animals cured is amazing considering what we were up against."
Gendelman
said its unclear how long it will take before clinical trials can begin
noting that more research needs to be done into the potential of
toxicity of gene modifying therapy and how to scale up the dose for
humans.
"We're working on this day and night and
we hope it'll be sooner than later, but we have some obstacles to
overcome," he said. "There’s a tremendous amount of effort to move this
technology forward."

No comments:
Post a Comment